Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Source: SeekingAlpha
2026-02-11 08:43:11 ET
...
Read the full article on Seeking Alpha
For further details see:
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Spero Therapeutics Inc.
NASDAQ: SPRO
SPRO Trading
0.44% G/L:
$2.26 Last:
52,127 Volume:
$2.27 Open:
SPRO Latest News
December 19, 2025 08:00:00 am
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
November 13, 2025 04:05:00 pm
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
SPRO Stock Data
$132,679,040
44,000,989
3.11%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
